Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Maron, Martin S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

cardiovascular magnetic resonance; fibrosis; heart failure; Hypertrophic cardiomyopathy; sudden death

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ABLATION THERAPY; ANEURYSM; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE ANEURYSM; HEART LEFT VENTRICLE HYPERTROPHY; HEART PAPILLARY MUSCLE; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MITRAL VALVE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; DISEASE COURSE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FIBROSIS; GENETIC PREDISPOSITION; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MITRAL VALVE; MYOCARDIUM; PAPILLARY MUSCLES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84860577086     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-13     Document Type: Review

References (119)

1. Hypertrophic cardiomyopathy: a systematic review. Maron BJ, JAMA 2002 287 1308 20 (Pubitemid 34250486)
2. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Wigle ED, Rakowski H, Kimball BP, Williams WG, Circulation 1995 92 1680 92
3. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED, J Am Coll Cardiol 2003 42 1687 713 (Pubitemid 37383745)
4. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. Alcalai R, Seidman JG, Seidman CE, J Cardiovasc Electrophysiol 2008 19 104 10
5. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Seidman JG, Seidman C, Cell 2001 104 557 67 (Pubitemid 32201950)
6. The importance of the site and the extent of hypertrophy. A review. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG, Hypertrophic cardiomyopathy, Prog Cardiovasc Dis 1985 28 1 83 (Pubitemid 15237515)
7. Hypertrophic cardiomyopathy: an important global disease. Maron BJ, Am J Med 2004 116 63 5 (Pubitemid 38050032)
8. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ, J Am Coll Cardiol 2005 46 480 7 (Pubitemid 41040290)
9. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ, J Am Coll Cardiol 1995 26 1529 36
10. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. Maron BJ, Casey SA, Hauser RG, Aeppli DM, J Am Coll Cardiol 2003 42 882 8 (Pubitemid 37069223)
11. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM, JAMA 1999 281 650 5 (Pubitemid 29098067)
12. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ, J Am Coll Cardiol 2000 36 2212 8
13. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F, Circulation 2000 102 858 64
14. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, Bellini N, Smaniotto G, Zuachetto M, Iliceto S, Thiene G, Maron BJ, Eur Heart J 2010 31 2111 23
15. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ, Circulation 2001 104 2517 24 (Pubitemid 33107372)
16. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ, J Am Coll Cardiol 2002 39 2042 8 (Pubitemid 34628288)
17. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Ho CY, Circulation 2010 122 2430 40
18. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE, J Clin Invest 1992 90 1666 71
19. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, Seidman CE, J Am Coll Cardiol 2001 38 315 21 (Pubitemid 32721755)
20. A new era in clinical genetic testing for hypertrophic cardiomyopathy. Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA, J Cardiovasc Transl Res 2009 2 381 91
21. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy: Bos JM, Towbin JA, Ackerman MJ, J Am Coll Cardiol 2009 54 201 11
22. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG, N Engl J Med 1992 326 1108 14
23. Clinical Challenges of Genotype Positive (+)-Phenotype Negative (-) Family Members in Hypertrophic Cardiomyopathy. Maron BJ, Yeates L, Semsarian C, Am J Cardiol 2010
24. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman JG, Seidman CE, JAMA 2009 301 1253 9
25. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, Tajik AJ, Gersh BJ, Circulation 2002 106 3085 90 (Pubitemid 35440293)
26. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Maron BJ, Circulation 2010 121 445 56
27. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ, Mayo Clinic proceedings 2006 81 459 67
28. The expanding prognostic role of late gadolinium enhanced cardiac magnetic resonance. Kramer CM, J Am Coll Cardiol 2006 48 1986 7
29. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E, J Am Coll Cardiol 2009 54 220 8
30. Cardiovascular magnetic resonance. Pennell DJ, Circulation 2010 121 692 705
31. Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm. Reichek N, Gupta D, J Am Coll Cardiol 2008 52 567 8
32. The emerging role of MRI in the diagnosis and management of cardiomyopathies. Rochitte CE, Tassi EM, Shiozaki AA, Curr Cardiol Rep 2006 8 44 52
33. The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy. Moon JC, McKenna WJ, Nat Clin Pract Cardiovasc Med 2009 6 166 7
34. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. O'Hanlon R, Assomull RG, Prasad SK, Curr Cardiol Rep 2007 9 51 6 (Pubitemid 46546688)
35. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ, Circulation 2005 112 855 61 (Pubitemid 41170072)
36. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Sahlosser T, Sabin GV, Sechtem U, Marholdt H, J Am Coll Cardiol 2010 56 875 87
37. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ, Circ Heart Fail 2008 1 184 91
38. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciaselli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, J Am Coll Cardiol 2010 56 867 74
39. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ, Circ Heart Fail 2010 3 51 8
40. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. Klues HG, Schiffers A, Maron BJ, J Am Coll Cardiol 1995 26 1699 708
41. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, Goldstein S, Hung J, Maron MS, Ommen SR, Woo A, J Am Soc Echocardiogr 2011 24 473 98
42. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Maron MS, Lesser JR, Maron BJ, Am J Cardiol 2010 105 1842 3
43. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Moon JC, Fisher NG, McKenna WJ, Pennell DJ, Heart 2004 90 645 9 (Pubitemid 38668538)
44. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Fattori R, Biagini E, Lorenzini M, Buttazzi K, Lovato L, Rapezzi C, Am J Cardiol 2010 105 1592 6
45. Apical hypertrophic cardiomyopathy: diagnosed by cardiac magnetic resonance imaging. Ates M, Kwong RY, Lipton MJ, Tatli S, Tex Heart Inst J 2006 33 408 9 (Pubitemid 44683449)
46. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santi M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ, J Am Coll Cardiol 2008 52 559 66
47. Right ventricular involvement in hypertrophic cardiomyopathy. Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, Manning WJ, Am J Cardiol 2007 100 1293 8 (Pubitemid 47500158)
48. Right ventricular hypertrophy and scarring in mutation positive hypertrophic cardiomyopathy. Keeling AN, Carr JC, Choudhury L, European heart journal 2010 31 381
49. Hypertrophic cardiomyopathy complicated by large apical aneurysm and thrombus, presenting as ventricular tachycardia. Holloway CJ, Betts TR, Neubauer S, Myerson SG, J Am Coll Cardiol 2010 56 1961
50. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ, Circulation 2008 118 1541 9
51. Hypertrophic cardiomyopathy with left ventricular apical aneurysm in brothers. Shenoy C, Maron MS, Am J Cardiol 2011 108 612 3
52. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. Lim KK, Maron BJ, Knight BP, J Cardiovasc Electrophysiol 2009 20 445 7
53. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ, Circulation 2011 124 40 7
54. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, Udelson JE, Manning WJ, Maron BJ, Am J Cardiol 2008 101 668 73 (Pubitemid 351635561)
55. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P, Garcia MJ, Lever HM, Desai MY, Heart 2008 94 1295 301
56. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, van Rossum AC, J Am Coll Cardiol 2006 48 2518 23 (Pubitemid 44881223)
57. Prevalence, Clinical Profile and Prognostic Significance of Myocardial Crypts in Hypertrophic Cardiomyopathy. Maron MS RE, Lin D, Applebaum E, Gibson CM, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ, J Am Col Cardiol 2011 57 191
58. Cardiovascular Magnetic Resonance Imaging in a Genotype Positive-Phenotype Negative Hypertrophic Cardiomyopathy Patient. Rowin EJ, Maron MS, Lesser JR, Maron BJ, JACC Cardiovasc Imaging 2012 5 119 122
59. Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype. Strijack B, Ariyarajah V, Soni R, Jassal DS, Greenberg CR, McGregor R, Morris A, J Cardiovasc Magn Reson 2008 10 58
60. Inducible malignant ventricular tachyarrhythmia in a patient with genotyped hypertrophic cardiomyopathy in absence of left ventricular hypertrophy or enlargement. Ariyarajah V, Tam JW, Khadem A, Circulation 2009 119 543 4
61. Imaging phenotype versus genotype in hypertrophic cardiomyopathy. Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM, Circ Cardiovasc Imaging 2011 4 156 68
62. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG, N Engl J Med 2005 352 362 72
63. Cardiovascular magnetic resonance in cardiac amyloidosis. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ, Circulation 2005 111 186 93 (Pubitemid 40139730)
64. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Gange CA, Link MS, Maron MS, Circulation 2009 120 96 7
65. Overlapping phenotypes: left ventricular noncompaction and hypertrophic cardiomyopathy. Kelley-Hedgepeth A, Towbin JA, Maron MS, Circulation 2009 119 588 9
66. Apical hypertrophic cardiomyopathy or left ventricular non-compaction? A difficult differential diagnosis. Spirito P, Autore C, Eur Heart J 2007 28 1923 4 (Pubitemid 47579553)
67. Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Maron BJ, British journal of sports medicine 2009 43 649 56
68. Troponin release following endurance exercise: is inflammation the cause? a cardiovascular magnetic resonance study. O'Hanlon R, Wilson M, Wage R, Smith G, Alpendurada FD, Wong J, Dahl A, Oxborough D, Godfrey R, Sharma S, Roughton M, George K, Pennell DJ, Whyte G, Prasad SK, J Cardiovasc Magn Reson 2010 12 38
69. Left ventricular outflow tract planimetry by cardiovascular magnetic resonance differentiates obstructive from non-obstructive hypertrophic cardiomyopathy. Schulz-Menger J, Abdel-Aty H, Busjahn A, Wassmuth R, Pilz B, Dietz R, Friedrich MG, J Cardiovasc Magn Reson 2006 8 741 6 (Pubitemid 44195996)
70. Clinical practice. Hypertrophic obstructive cardiomyopathy. Nishimura RA, Holmes DR Jr, N Engl J Med 2004 350 1320 7 (Pubitemid 38375367)
71. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA, J Am Coll Cardiol 2005 46 470 6 (Pubitemid 41040288)
72. Myectomy plus Alfieri technique for outflow tract obstruction in hypertrophic cardiomyopathy. Sado DM, Flett AS, McGregor CG, Pantazis AA, Elliott PM, Moon JC, Circulation 2010 122 938 9
73. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, Biagini E, Vletter WB, Serruys PW, Circulation 2005 112 482 8 (Pubitemid 41060787)
74. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK, J Thorac Cardiovasc Surg 2004 127 481 9 (Pubitemid 38180530)
75. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR, J Am Coll Cardiol 2010 55 823 34
76. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ, J Am Coll Cardiol 2007 49 350 7 (Pubitemid 46097376)
77. Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F, Yang W, Am J Cardiol 2010 106 1487 91
78. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ, N Engl J Med 2000 342 1778 85 (Pubitemid 30390237)
79. The case for myocardial ischemia in hypertrophic cardiomyopathy. Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Maron BJ, J Am Coll Cardiol 2009 54 866 75
80. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. Knaapen P, van Dockum WG, Gotte MJ, Broeze KA, Kuijer JP, Zwanenburg JJ, J Nucl Cardiol 2006 13 660 7 (Pubitemid 44283785)
81. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I, Pupi A, Camici PG, Cecchi F, J Nucl Med 2008 49 1090 6 (Pubitemid 351948017)
82. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, J Am Coll Cardiol 2009 54 242 9
83. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F, Torricelli F, Camici PG, J Am Coll Cardiol 2006 47 1043 8
84. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ, Circulation 2006 114 216 25 (Pubitemid 44297115)
85. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ, J Am Coll Cardiol 2004 43 2260 4 (Pubitemid 38757595)
86. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. Papavassiliu T, Schnabel P, Schroder M, Borggrefe M, European heart journal 2005 26 2395 (Pubitemid 41552968)
87. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ, J Am Coll Cardiol 2003 41 1561 7 (Pubitemid 36543376)
88. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, Bonow RO, Judd RM, Kim RJ, J Am Coll Cardiol 2002 40 2156 64 (Pubitemid 36005903)
89. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS, Am J Cardiol 2010 106 261 7
90. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ, N Engl J Med 2003 348 295 303 (Pubitemid 36119984)
91. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, Appelbaum E, Main ML, Roberts WC, Am J Cardiol 2008 101 544 7 (Pubitemid 351200495)
92. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. Bongioanni S, Spirito P, Masi AS, Chiribiri A, Bonamini R, Conte MR, Circ Cardiovasc Imaging 2009 2 349 50
93. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS, J Am Coll Cardiol 2008 51 1369 74 (Pubitemid 351443083)
94. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T, J Cardiovasc Magn Reson 2010 12 30
95. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Int J Cardiovasc Imaging 2008 24 617 25
96. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Suk T, Edwards C, Hart H, Christiansen JP, Heart Lung Circ 2008 17 370 4
97. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Aquaro GD, Masci P, Formisano F, Barison A, Strata E, Pingitore A, Positano V, Spirito P, Lombardi M, Am J Cardiol 2010 105 392 7
98. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ, J Am Coll Cardiol 2003 42 873 9 (Pubitemid 37059747)
99. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance: the future looks bright. Salerno M, Kramer CM, J Am Coll Cardiol 2010 56 888 9
100. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? Kim RJ, Judd RM, J Am Coll Cardiol 2003 41 1568 72 (Pubitemid 36543377)
101. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM, Circulation 1999 100 1992 2002 (Pubitemid 29529292)
102. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H, Circulation 2007 115 2418 25 (Pubitemid 46717964)
103. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM, The New England journal of medicine 2000 343 1445 53
104. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Kuribayashi T, Roberts WC, Am J Cardiol 1992 70 1333 40
105. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK, Lima JA, Wu KC, Circulation 2007 115 2006 14 (Pubitemid 46625951)
106. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY, Circulation 2006 114 32 9 (Pubitemid 44305272)
107. Extent of Intermediate Signal Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrythmias in Patients with Hypertrophic Cardiomyopathy. Appelbaum EMB, Adabag S, Hauser TH, Lesser JR, Haas TS, Riley A, Harrigan CJ, Delling F, Udelson JE, Gibson CM, Manning WJ, Maron MS, Circ Cardiovasc Imaging 2011
108. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy. Aquaro GD, Positano V, Pingitore A, Strata E, Di Bella G, Formisano F, Spirito P, Lombardi M, J Cardiovasc Magn Reson 2010 12 21
109. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Milosz B, Polanska M, Puzylio W, Eur J Radiol 2010 74 149 53
110. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C, Br Heart J 1986 55 575 81 (Pubitemid 16092908)
111. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC, JACC Cardiovascular imaging 2011 4 150 6
112. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, Appelbaum E, Radiology 2011 258 128 33
113. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. Amado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R, Nasir K, Kraitchman DC, Lima JA, J Am Coll Cardiol 2004 44 2383 9 (Pubitemid 39647614)
114. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A, Hum Pathol 2000 31 988 98
115. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. Shirani J, Pick R, Roberts WC, Maron BJ, J Am Coll Cardiol 2000 35 36 44 (Pubitemid 30061256)
116. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ, Heart 2000 84 476 82
117. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. Kim HW, Farzaneh-Far A, Kim RJ, J Am Coll Cardiol 2009 55 1 16
118. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC, Circulation 2010 122 138 44
119. Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Huber AM, Schoenberg SO, Hayes C, Spannagl B, Engelmann MG, Franz WM, Radiology 2005 237 854 60 (Pubitemid 41636372)